Tuesday, May 27, 2025 at 12:30Pm Pacific
VIRTUAL EVENT
Data Dumplings and Due Diligence: Behind the Biotech Investor Curtain 

Raising capital is never easy — and in this market, it’s brutal for biotech. So what are investors looking for right now? And how can you build relationships long before your financing effort?

Seasoned biotech investors, Michele Park of NEA, Bong Koh of Venrock, and Chen Yu of TCGX shared their insights from their experience of refining strategies and weathering market shifts. 

About the speakers

Michele joined NEA in 2021. She serves on several boards including Abcuro, a clinical-stage company developing a first-in-class KLRG1-targeting antibody for Inclusion Body Myositis (IBM), where she led its recent Series C financing of $200 million. She was previously an investor at Clarus Ventures (now Blackstone Life Sciences). 

Bong works predominantly on Venrock’s public and cross-over biotech fund, Venrock Healthcare Capital Partners. With over 20 years of investment experience, he has led the financing for numerous biotech companies and served on the board of directors for Artiva Biotherapeutics, AveXis (acquired by Novartis for $8.7 billion) and RayzeBio (acquired by Bristol Myers Squibb for $4.1 billion).

Chen is the founder and managing partner at TCGX, a healthcare investment firm. Prior to TCGX, Chen spent sixteen years as a managing partner at Vivo Capital, a life sciences focused investor with $4.5 billion assets under management. He has extensive operating experience with leadership roles at both private and public companies, including stints as the COO of Sagent Pharmaceuticals and CBO of China KangHui, both of which went public and were ultimately acquired.